Liver‐expressed antimicrobial peptide 2 is associated with improved pancreatic insulin secretion in adults with overweight and obesity
Authors' conclusion
These results provide important insights into the association between LEAP2 and cardiometabolic health in a high-risk population of individuals with overweight and obesity. This is a first report of an association between LEAP2 and insulin secretion, insulin sensitivity and NFκB activity. LEAP2 may represent an important potential therapeutic target to promote insulin secretion in people with type 2 diabetes and obesity.
Study context
- Population
- Adults with overweight or obesity; 63.1% male, mean age 31.3 ± 8.5 years
- Participants
- 65 adults
- Outcome
- Associations of LEAP2 levels with cardiometabolic risk factors (body composition, insulin and glucose metabolism, plasma lipids, inflammation markers)
Main finding
As reported in the abstract
Associations of LEAP2 with cardiometabolic risk factors
- LEAP2 associated with total body fat, but not with BMI or WHR (univariable and age- and sex-adjusted models)
- P < 0.05
- Higher LEAP2 positively associated with higher insulin secretion, univariable
- P = 0.047
- Higher LEAP2 positively associated with higher insulin secretion, adjusted for age, sex and body fat
- P = 0.03
- No association with fasting glucose
- P ≥ 0.05
- Higher LEAP2 associated with insulin resistance, adjusted for age and sex
- P = 0.07
- Association with insulin resistance disappeared after additional adjustment for body fat
- P = 0.2
- Inverse association between LEAP2 and NFκB activity in peripheral blood mononuclear cells (age-, sex- and body fat-adjusted)
- P = 0.04
Observational data: associations, not effects.
Original publication
Liver‐expressed antimicrobial peptide 2 is associated with improved pancreatic insulin secretion in adults with overweight and obesity. Diabetes Obes Metab. Published 19 January 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →